Cargando…

QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease

Parkinson’s disease is one of the most common neurodegenerative illnesses in older persons and the leucine-rich repeat kinase 2 (LRRK2) is an auspicious target for its pharmacological treatment. In this work, quantitative structure–activity relationship (QSAR) models for identification of putative i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastián-Pérez, Víctor, Martínez, María Jimena, Gil, Carmen, Campillo, Nuria Eugenia, Martínez, Ana, Ponzoni, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798859/
https://www.ncbi.nlm.nih.gov/pubmed/30763264
http://dx.doi.org/10.1515/jib-2018-0063
_version_ 1783460150464479232
author Sebastián-Pérez, Víctor
Martínez, María Jimena
Gil, Carmen
Campillo, Nuria Eugenia
Martínez, Ana
Ponzoni, Ignacio
author_facet Sebastián-Pérez, Víctor
Martínez, María Jimena
Gil, Carmen
Campillo, Nuria Eugenia
Martínez, Ana
Ponzoni, Ignacio
author_sort Sebastián-Pérez, Víctor
collection PubMed
description Parkinson’s disease is one of the most common neurodegenerative illnesses in older persons and the leucine-rich repeat kinase 2 (LRRK2) is an auspicious target for its pharmacological treatment. In this work, quantitative structure–activity relationship (QSAR) models for identification of putative inhibitors of LRRK2 protein are developed by using an in-house chemical library and several machine learning techniques. The methodology applied in this paper has two steps: first, alternative subsets of molecular descriptors useful for characterizing LRRK2 inhibitors are chosen by a multi-objective feature selection method; secondly, QSAR models are learned by using these subsets and three different strategies for supervised learning. The qualities of all these QSAR models are compared by classical metrics and the best models are discussed in statistical and physicochemical terms.
format Online
Article
Text
id pubmed-6798859
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-67988592019-10-28 QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease Sebastián-Pérez, Víctor Martínez, María Jimena Gil, Carmen Campillo, Nuria Eugenia Martínez, Ana Ponzoni, Ignacio J Integr Bioinform Workshops Parkinson’s disease is one of the most common neurodegenerative illnesses in older persons and the leucine-rich repeat kinase 2 (LRRK2) is an auspicious target for its pharmacological treatment. In this work, quantitative structure–activity relationship (QSAR) models for identification of putative inhibitors of LRRK2 protein are developed by using an in-house chemical library and several machine learning techniques. The methodology applied in this paper has two steps: first, alternative subsets of molecular descriptors useful for characterizing LRRK2 inhibitors are chosen by a multi-objective feature selection method; secondly, QSAR models are learned by using these subsets and three different strategies for supervised learning. The qualities of all these QSAR models are compared by classical metrics and the best models are discussed in statistical and physicochemical terms. De Gruyter 2019-02-14 /pmc/articles/PMC6798859/ /pubmed/30763264 http://dx.doi.org/10.1515/jib-2018-0063 Text en ©2019, Víctor Sebastián-Pérez et al., published by Walter de Gruyter GmbH, Berlin/Boston http://creativecommons.org/licenses/by/4.0 This work is licensed under the Creative Commons Attribution 4.0 Public License.
spellingShingle Workshops
Sebastián-Pérez, Víctor
Martínez, María Jimena
Gil, Carmen
Campillo, Nuria Eugenia
Martínez, Ana
Ponzoni, Ignacio
QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
title QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
title_full QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
title_fullStr QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
title_full_unstemmed QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
title_short QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
title_sort qsar modelling to identify lrrk2 inhibitors for parkinson’s disease
topic Workshops
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798859/
https://www.ncbi.nlm.nih.gov/pubmed/30763264
http://dx.doi.org/10.1515/jib-2018-0063
work_keys_str_mv AT sebastianperezvictor qsarmodellingtoidentifylrrk2inhibitorsforparkinsonsdisease
AT martinezmariajimena qsarmodellingtoidentifylrrk2inhibitorsforparkinsonsdisease
AT gilcarmen qsarmodellingtoidentifylrrk2inhibitorsforparkinsonsdisease
AT campillonuriaeugenia qsarmodellingtoidentifylrrk2inhibitorsforparkinsonsdisease
AT martinezana qsarmodellingtoidentifylrrk2inhibitorsforparkinsonsdisease
AT ponzoniignacio qsarmodellingtoidentifylrrk2inhibitorsforparkinsonsdisease